OBR Oncology’s Friday daily newsfeed included AJMC® coverage of the 2018 Community Oncology Conference hosted by the Community Oncology Alliance. The article, “Commissioner Gottlieb Updates Community Oncologists on the FDA’s Mission to Improve Access,” covered Gottlieb’s overview of current and future plans of the regulatory agency, particularly in their strides within the molecular diagnostic testing space.
An article in EHR Intelligence on specialty electronic health record (EHR) products being linked to high physician satisfaction included a study published in AJMC®. The study, “Electronic Health Record ‘Super-Users’ and ‘Under-Users’ in Ambulatory Care Practices,” found that nearly 40% of US ambulatory care practices are “under-users” of health information technology functionalities, which impacts the ability of the health system as a whole to provide coordinated, efficient care.
RevCycle Intelligence’s article on value-based purchasing mentioned the AJMC®-published study, “Value-Based Contracting Innovated Medicare Advantage Healthcare Delivery and Improved Survival.” The study concluded that elderly Medicare Advantage members with multiple chronic conditions attained a survival benefit from more cost-effective care when a private plan developed gainshare and monetary risk-bearing arrangements with its contracted providers.
The Center for Biosimilars®, a sister publication of AJMC®, highlighted a study published in AJMC®’s April issue. The authors of the study, “Limited Distribution Networks Stifle Competition in the Generic and Biosimilar Drug Industries,” examined limited distribution networks and determined that drug companies employ these networks to obstruct access to drug samples sought by competitor companies in order to conduct necessary testing to submit a generic or biosimilar drug application to the FDA.
The National Association of Chain Drug Stores included an article from AJMC® in its daily newsfeed on Monday. The article, “FDA Approves Rucaparib for Maintenance in Recurrent Ovarian Cancer,” reported on the FDA’s approval of the PARP inhibitor for maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.